课题基金 / 基金详情

A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities

A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities
一种新型机器人废水分析系统,用于量化住宅社区中阿片类药物的暴露和处理
批准号:
10549579
负责人:
Peter R Chai
金额:
$17.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-02-01 至 2023-12-31
关键词:
2019-nCoVAccident and Emergency departmentAddressAdministrative SupplementAmericanAreaBackBehavior TherapyBenchmarkingBiologicalBiological AssayBiological MarkersBusinessesCOVID-19COVID-19 assayCOVID-19 surveillanceCaringCatchment AreaChemicalsChronicCitiesClinicClinicalCocaineCollectionCommunitiesConsumptionCounselingCross-Sectional StudiesDataDetectionDevelopmentDrug ScreeningDrug usageEmergency medical serviceGlucuronidesHIV InfectionsHarm ReductionHigh Pressure Liquid ChromatographyHospitalsHumanIndividualInfrastructureInterventionJournalsKetamineLifeLinkLocationMass Spectrum AnalysisMassachusettsMeasuresMedicalMental HealthMethamphetamineMethamphetamine use disorderMethodsMissionMorbidity - disease rateMunicipalitiesNaloxoneNeighborhoodsOpioidParentsPathway interactionsPatient Self-ReportPharmaceutical PreparationsPharmacologic SubstancePharmacotherapyPharmacy facilityPhencyclidinePlantsPopulationPositioning AttributePrecision HealthPreparationPrevalencePsychiatric therapeutic procedurePublic HealthPublic PolicyRecoveryReportingResource AllocationRoboticsSamplingScreening ResultSewageSiteSmall Business Innovation Research GrantSubstance Use DisorderSurveillance ProgramSurveysSystemSystems AnalysisTechniquesTimeToxic effectToxicologyTraumaUnited StatesUrineValidationVulnerable PopulationsWaterWorkbasecomorbiditydata visualizationdrug developmenteffective interventioneffective therapyendo-alpha-sialidasehealth care service utilizationhigh riskinjection drug useinnovationinsightinstrumentinterestmedical schoolsmedication nonadherencemortalitymultidisciplinarynovelopioid epidemicopioid exposureopioid use disorderoutreachparent grantpeerpopulation healthprescription opioidprescription stimulantsprogramspsychostimulantpublic health prioritiespublic health relevanceresponsesample collectionstimulant usestimulant use disorderstimulant usersubstance usesuccesssurveillance datasurveillance strategytrendwastewater epidemiologywastewater sampleswastewater surveillance

项目摘要

项目成果

Peter R Chai的其他基金

相关文献

中文摘要
翻译
抽象的。 美国各地非法使用精神刺激剂的情况正在增加,导致严重的发病率和死亡率。一个 2019年的横断面研究发现,在美国,自我报告的甲基苯丙胺使用障碍者 自2015年以来增长了两倍。与甲基苯丙胺和其他药物相关的下游并发症 可卡因、氯胺酮和苯环利定等精神刺激剂会增加医疗保健利用率, 不坚持用药,药物使用的感染性并发症,以及日益恶化的精神健康和创伤。 尽管它很重要,但对精神刺激剂使用的监测仍然是次优的;大多数现有的监测 战略利用大量国家自我报告抽样或来自急诊科和药物使用情况的数据 临床尿液药物筛查混乱,造成明显的偏倚。该监视数据被用来通知 国家公共卫生优先事项和在社区范围内分配资源以解决物质使用问题 精神错乱。以废水为基础的流行病学是进行人群水平药物监测的潜在选择。 通过测量废水网络中的关键母体化合物和代谢物,估计药物的流行率 可以可视化地显示使用情况和随时间变化的使用趋势。通过改变样本采集在 废水网络,物质使用数据可以描述在一个大型污水处理厂的集水区 通过测量个别街道水平的沙井中的物质,在区域或社区一级进行监测。我们正在进行的斋戒 Track SBIR利用废水网络开发一种阿片类药物测试并将其商业化,该测试可以测量 母体阿片类药物以及表明消费的关键代谢物。这份行政副刊重复了 我们的成功家长通过选择四种精神刺激剂
英文摘要
ABSTRACT. Illicit psychostimulant use is increasing across the United States leading to significant morbidity and mortality. A 2019 cross sectional study found that individuals with self reported methamphetamine use disorder in the US has tripled since 2015. The downstream comorbidities associated with methamphetamine and other psychostimulants like cocaine, ketamine and phencyclidine result in increased healthcare utilization, medication nonadherence, infectious complications of drug use, and worsening mental health and trauma. Despite its importance, surveillance of psychostimulant use remains suboptimal; most existing surveillance strategies utilize large national self-report sampling or data from emergency department and substance use disorder clinic urine drug screens resulting in significant bias. This surveillance data is utilized to inform national public health priorities and on a community scale, allocation of resources to address substance use disorders. Wastewater-based epidemiology is a potential option to conduct population level drug surveillance. By measuring key parent compound and metabolites in wastewater networks, a prevalence estimate of drug use and trends of use over time can be visualized. By varying the location of sample collection in the wastewater network, substance use data can be described at a large wastewater treatment plant catchment area or at the community level by measuring substances at individual street level manholes. Our ongoing fast track SBIR leverages wastewater networks to develop and commercialize an opioid assay that measures both parent opioids as well as key metabolites that indicate consumption. This administrative supplement iterates on our successful parent grant by selecting four psychostimulants of
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1017/dmp.2023.52
发表时间: 2023-05-09
期刊: DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
影响因子: 2.7
作者: [Erickson, Timothy B., Harvin, Donell, Schmid, Alexis, Loevinsohn, Gideon, Poriechna, Anna, Martyshyn, Oleg, Kliukach, Kryrylo, Sydlowski, Meaghan, Strong, Jonathan, Kivlehan, Sean M.]
通讯作者: Kivlehan, Sean M.
DOI: 10.3389/fpubh.2022.987159
发表时间: 2022
期刊: FRONTIERS IN PUBLIC HEALTH
影响因子: 5.2
作者: [Prakash, Jaya, Erickson, Timothy B., Stoklosa, Hanni]
通讯作者: Stoklosa, Hanni
Ketamine for the treatment for opioid use disorder and suicidal ideation in the emergency department
  • 批准号:
    10646993
  • 项目类别:
  • 资助金额:
    $22.38万
  • 财政年份:
    2023
  • 负责人:
    Peter R Chai
  • 依托单位:
Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trial
  • 批准号:
    10593244
  • 项目类别:
  • 资助金额:
    $25.73万
  • 财政年份:
    2022
  • 负责人:
    Peter R Chai
  • 依托单位:
Smart Steps: A context-aware adherence intervention to improve PrEP adherence among men who have sex with men (MSM) with substance use disorder
  • 批准号:
    10468388
  • 项目类别:
  • 资助金额:
    $268.5万
  • 财政年份:
    2022
  • 负责人:
    Peter R Chai
  • 依托单位:
Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trial
  • 批准号:
    10703512
  • 项目类别:
  • 资助金额:
    $21.26万
  • 财政年份:
    2022
  • 负责人:
    Peter R Chai
  • 依托单位: